Detailed Narrative
Q4 & FY26 Financial Performance Overview
Ipca Laboratories reported a consolidated revenue of ₹9,646 crores for FY26, marking an 8% growth over FY25. The consolidated EBITDA margin improved by 1.78% to 20.72% in FY26, surpassing the 20% guideline. Standalone EBITDA margins also saw a significant improvement of 2.52% to 25.18% for FY26. Q4 FY26 consolidated EBITDA margin was 20.52%, up 2.28% from Q4 FY25.
Domestic & Export Formulation Business Highlights
The domestic formulation business grew 10% in FY26 to ₹3,817 crores and 12% in Q4 FY26 to ₹853 crores. Ipca maintained its 16th rank in the MAT March '26 market, with market share marginally improving to 2.09%. The export formulation business grew 9% in FY26 to ₹2,083 crores. Promotional business showed strong growth of 14% in both Q4 and FY26, reaching ₹664 crores. Generic business (excluding tenders) grew 17% in FY26 to ₹1,149 crores, with a 39% growth in Q4 FY26.
API Business and US Market Performance
The API business delivered a 10% growth in FY26, reaching ₹1,396 crores. The consolidated US business, including Ipca USA and Unichem USA, grew 14% in FY26 to ₹1,567 crores and 10% in Q4 FY26 to ₹428 crores. Management expects the US business to continue growing at around 12-13% in the current financial year.
Margin Expansion Drivers and Cost Headwinds
The overall margin improvement was primarily attributed to favorable product mix changes, with strong performance in domestic, ROW, cardiac, and generic businesses, as well as improved API margins. However, Unichem's EBITDA margins declined from 12% to 8% in FY26, partially offsetting consolidated gains. Management anticipates overall material costs to rise by 10-12% and freight costs increased by ~25% in Q4 FY26 due to supply chain disruptions and geopolitical conflicts. They plan to offset these by passing on API cost increases and raising domestic decontrolled product prices by 6-7%.
Unichem Integration and Outlook
Unichem's U.S. business faced challenges in FY26, leading to a decline in EBITDA margins from 12% to 8%. However, management expects Unichem's US business to grow around 10% in the current financial year, with overall margins improving to 12-13%. This improvement is anticipated due to market share recovery, strong European performance, and cost savings from the closure of the Ireland facility (saving EUR 4-5 million in overheads) with production shifted to India.
Subsidiaries Performance and Strategic Initiatives
Trophic Wellness, a domestic subsidiary, contributed significantly with a business of around ₹125 crores and a profit of approximately ₹40 crores. One of Krebs' plants (Nellore) has become EBITDA positive, while another faces concerns. Onyx Scientific, a US research services subsidiary, is experiencing issues due to the current environment but shows signs of improvement. The UK subsidiary incurred a loss of EUR 2-3 million in FY26 due to adverse pricing, but management expects better performance. The Pisgah Labs US formulation facility is under construction and expected to be ready by Q4 FY27, with meaningful turnover anticipated from the next financial year.